Exploring Grid Dynamics Holdings And Two High Growth Tech Stocks

In This Article:

Over the last 7 days, the market has dropped 1.4%, but it is up 21% over the past year with earnings forecast to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks such as Grid Dynamics Holdings can be crucial for investors looking to capitalize on robust earnings potential and market resilience.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

TG Therapeutics

28.39%

43.54%

★★★★★★

Super Micro Computer

20.62%

27.13%

★★★★★★

Sarepta Therapeutics

24.22%

44.94%

★★★★★★

Ardelyx

27.44%

65.50%

★★★★★★

G1 Therapeutics

27.57%

57.75%

★★★★★★

Invivyd

42.91%

70.39%

★★★★★★

Amicus Therapeutics

20.45%

61.85%

★★★★★★

Ascendis Pharma

39.87%

68.71%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 248 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Grid Dynamics Holdings

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Grid Dynamics Holdings, Inc. provides technology consulting, platform and product engineering, and analytics services globally and has a market cap of approximately $1.03 billion.

Operations: Grid Dynamics Holdings, Inc. generates revenue primarily from its computer services segment, which accounted for $318.34 million. The company's operations span North America, Europe, and other international markets.

Grid Dynamics Holdings has demonstrated significant growth potential, with a forecasted annual revenue increase of 14%, surpassing the US market's average. Their innovative AI-powered Data Observability Starter Kit enhances data quality across diverse platforms, crucial for data-driven decision-making. Despite a net loss of $0.82 million in Q2 2024, their R&D expenses contribute to long-term growth, with earnings expected to grow 105.85% annually. The company’s forward-looking strategy includes robust product offerings and seamless integration capabilities, supporting enterprise-scale clients effectively.

NasdaqCM:GDYN Earnings and Revenue Growth as at Sep 2024
NasdaqCM:GDYN Earnings and Revenue Growth as at Sep 2024

Savara

Simply Wall St Growth Rating: ★★★★★☆

Overview: Savara Inc. is a clinical-stage biopharmaceutical company specializing in rare respiratory diseases with a market cap of $692.97 million.

Operations: Savara Inc. focuses on developing therapies for rare respiratory diseases. The company is currently in the clinical stage and does not yet generate revenue from product sales.